> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Merck Disappointing Data with Keytruda/Yervoy Combo
- URL: https://www.fdaweb.com/merck-disappointing-data-with-keytruda-yervoy-combo/
- Published: 2021-02-01T12:00:00.000Z
- Updated: 2026-09-14T16:44:51.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5148568

Merck says Phase 3 data from the KEYNOTE-598 study evaluating its anti-PD-1 therapy Keytruda (pembrolizumab) in combination with Bristol-Myers Squibb’s Yervoy (ipilimumab) compared with Keytruda monotherapy did not show improved overall survival (OS) or progression-free survival in patients with metastatic non-small cell lung cancer without EGFR or ALK genomic tumor aberrations and whose tumors express PD-L1\. The median OS was 21.4 months for patients randomized to Keytruda in combination with ipilimumab versus 21.9 months for those randomized to Keytruda monotherapy, according to Merck. “Additionally, the median PFS was 8.2 months for patients in the combination arm versus 8.4 months for those in the Keytruda monotherapy arm,” it says, adding that those receiving the combination were more likely to experience serious side effects than those who received Keytruda alone.